Top

Cancer Chemotherapy and Pharmacology

Published in:

01-09-2008 | Original Article

Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients

Authors: Jens Atzpodien, Kerstin Terfloth, Michael Fluck, Martina Reitz

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2008

Abstract

Purpose

The efficacy of cisplatin, gemcitabine, and treosulfan (CGT) was evaluated in patients with chemotherapy pretreated relapsed AJCC stage IV uveal malignant melanoma.

Methods

Patients received i.v./intrahepatic cisplatin, i.v. gemcitabine, and i.v. treosulfan (CGT) on day 1 and 8 as first-line (n = 1), second-line (n = 9), third-line (n = 1) or fourth-line (n = 1) therapy. Cisplatin, gemcitabine, and treosulfan (CGT)-therapy was repeated every 5 weeks until progression of disease occurred. A maximum of six CGT-cycles (mean, 2 cycles) was administered per patient.

Results

No objective response was observed, six patients (50%) had stable disease and six (50%) patients progressed upon first reevaluation. Overall survival of all the 12 patients was 6 months. Patients with stable disease reached a median overall survival of 12 months, while patients with disease progression upon first reevaluation had a median overall survival of 4 months, only. Grade III/IV related hematotological side effects were experienced in six (leukopenia) and four (thrombocytopenia) patients.

Conclusions

Treatment with CGT may lead to disease stabilization and prolonged survival in a substantial proportion of progressive stage IV uveal melanoma patients, even following heavy chemotherapy treatment.

Flaherty LE, Unger JM, Liu PY, Mertens WC, Sondak VK (1998) Metastatic melanoma from intraocular primary tumors: the southwest oncology group experience in phase II advanced melanoma clinical trials. Am J Clin Oncol 21(6):568–572PubMedCrossRef

Bedikian AY, Legha SS, Mavligit G et al (1995) Treatment of uveal melanoma metastatic to the liver. Cancer 76(9):1665–1670PubMedCrossRef

Collaborative Ocular Melanoma Study Group (2001) Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the collaborative ocular melanoma study (COMS): COMS report no. 15. Arch Ophthalmol 119(5):670–676

Becker JC, Terheyden P, Kämpgen E et al (2002) Treatment of disseminated ocular melanoma with sequential fotemustine, interpheron alpha, and interleukin 2. Br J Cancer 87(8):840–845PubMedCrossRef

Kivelä T, Suciu S, Hansson J et al (2002) Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 39(8):1115–1120CrossRef

Mavligit GM, Charnsangavej C, Carrasco CH et al (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260(7):974–976PubMedCrossRef

Leyvraz S, Spataro V, Bauer J et al (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15(7):2589–2595PubMed

Neale MH, Myatt NE, Khoury GG et al (2001) Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 11(6):601–609PubMedCrossRef

Iwasaki H, Huang P, Keating MJ, Plunkett W (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270–278PubMed

10.

Schmittel A, Schmidt-Hieber M, Martus P et al (2006) A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma. Ann Oncol 17(12):1826–1829PubMedCrossRef

11.

Schmittel A, Scheulen ME, Bechrakis NE et al (2005) Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma. Melanoma Res 15(3):205–207PubMedCrossRef

Title: Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients
Authors: Jens Atzpodien
Kerstin Terfloth
Michael Fluck
Martina Reitz
Publication date: 01-09-2008
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2008
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-007-0655-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2008

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4

Biological properties of 4-methyl-2,7-diamino-5,10-diphenyl-4,9-diazapyrenium hydrogensulfate (ADAP)

Pharmacokinetics of heated intraperitoneal oxaliplatin

Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient

Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide

Keynote webinar | Spotlight on antibody–drug conjugates in cancer